Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
MaxCyte ( (MXCT) ) just unveiled an update.
On November 12, 2025, MaxCyte reported its third-quarter financial results, showing a total revenue of $6.8 million, a 16% decrease from the previous year. Despite the decline, the company reiterated its 2025 revenue guidance and announced an operational restructuring to reduce costs and accelerate profitability. MaxCyte added a new SPL client, Moonlight Bio, bringing the total number of SPL agreements to 32, and remains committed to investing in product enhancements and expanding its cell engineering offerings.
The most recent analyst rating on (MXCT) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on MaxCyte stock, see the MXCT Stock Forecast page.
Spark’s Take on MXCT Stock
According to Spark, TipRanks’ AI Analyst, MXCT is a Neutral.
MaxCyte’s financial challenges and valuation concerns weigh heavily on the stock’s score. However, strong shareholder support, strategic plans, and a solid cash position provide a basis for potential recovery, especially if operational efficiencies improve and macroeconomic conditions stabilize.
To see Spark’s full report on MXCT stock, click here.
More about MaxCyte
MaxCyte is a leading cell-engineering company that focuses on the discovery, development, and commercialization of next-generation cell therapies. The company offers platform technologies like Flow Electroporation® and SeQure DX™ gene editing risk assessment services, which enable precise and scalable cell engineering. MaxCyte supports researchers globally in developing safe and effective treatments for human health.
Average Trading Volume: 788,202
Technical Sentiment Signal: Sell
Current Market Cap: $156.7M
See more data about MXCT stock on TipRanks’ Stock Analysis page.